Type 2 Diabetes Tech: A Game-Changer Poised to Save Millions of Lives and Slash NHS Costs by Billions

Type II Diabetes is the fastest growing disease in the UK, and the leading cause of soaring rates of Cardio, Metabolic and Renal (CMR) diseases. CMR diseases are the leading cause of deaths and are crippling the NHS.  Increased screening with wearable tech is the only solution to prevent this looming national health disaster.

The NHS is already looking at trialling a revolutionary new at-home finger prick test to screen for diabetes (source:  BBC News 24/08/25), proposed to be rolled out in Northeast England initially, to find the ‘missing millions’ who are estimated to be living with diabetes without knowing it.

Dr Dawn Harper, NHS GP, TV Presenter, author and living with diabetes herself, is calling for CGM tech to support screening diagnoses.  Dr Dawn says: “Following my diagnosis I wore a CGM which gave me personalised data regarding my diet and sugar levels, which I could not have known any other way.  The information I was given from the GCM has enabled me to put my diabetes into remission, and I feel very strongly that everyone with prediabetes or Type II should be given the same opportunity to change their future.”

CGM (Continuous Glucose Monitors) are wearable devices that monitor blood glucose levels continuously in real time.  The data from CGM devices is sent to a smartphone or smartwatch, providing patients with detailed personalised insights into the lifestyle factors that cause glucose levels to become dangerously high or low (hyperglycaemia or hypoglycaemia). 

This information empowers behavioural change and personal healthcare management, enabling the individual to maintain their glucose levels within the safe range, thus preventing that person from developing the devastating complications and life-threatening diseases resulting from Type II Diabetes.

Increased screening will identify millions of ‘new’ diabetics’, however without the invaluable insights and support CGM tech provides, these newly diagnosed patients will not be able to effectively manage their disease and will go on to develop diseases including cancer, dementia, heart disease, kidney disease, severe mental illness and loss of eyesight and limbs.   

This catastrophic cost to both the nation’s health and the public purse will cripple the UK.